Navigation Links
CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
Date:8/30/2011

DURHAM, N.C., Aug. 30, 2011 /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has raised $7.5 million of a planned $9.5 million convertible note financing from its existing investors to support further late stage development of lasmiditan.  Participating in the financing were Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.

"This financing provides important working capital for CoLucid to further advance lasmiditan into Phase 3 development," remarked Thomas P. Mathers, Chief Executive Officer of CoLucid.  "We are embarking on additional clinical studies to further differentiate lasmiditan's safety profile from the triptan class of anti-migraine agents, as well as discussing with the FDA our final Phase 3 plans." said Mr. Mathers.

The Company is speaking with potential partners and is interacting with the FDA, and plans to advance lasmiditan into pivotal studies in 2012.

About Lasmiditan

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor 5-HT1B/1D receptors activated by triptans.

Five clinical studies have been successfully completed outside of the U.S., including a Phase 2b double blind placebo controlled oral dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia.  Importantly, because there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies, CoLucid expects the pivotal Phase 3 studies to confirm that lasmiditan's side effect profile is highly differentiated from triptans and ergotamines.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.

Media Contact: Kathy Kelly, CoLucid Pharmaceuticals, Inc., 919-806-4304, kkelly@colucid.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
2. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 BiondVax ... CEO, Dr. Ron Babecoff , will be attending the ... City . On Thursday, May 5, Dr. ... conference presented by Joseph Gunner & Co, taking ... BiondVax presentation that Dr. Babecoff will be using is downloadable ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Multiple Myeloma Market ... to their offering.       (Logo: ... Myeloma Market and Competitive Landscape Highlights 2016, ... products, Multiple Myeloma epidemiology, Multiple Myeloma market ...
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 04, 2016 , ... The Lymphoma Research Foundation (LRF) ā€“ ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Golf Club in Scarsdale, New York on May 23, 2016 for its annual ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Nike Rugby Camp's ... rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike Camp ... players every year since 2009. , ā€œIā€™m excited for our eighth summer here ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today announced its tenth anniversary ... What started out as an idea to provide a holistic approach to wellness ... , Developed by Dr. David Swanekamp, Chiropractic Physician , the wellness center offers ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... that supports cellular and metabolic health. This synergistic combination of omega-3 fatty acids ... along with 150 mg of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare facility Pearl ... following breast cancer surgery. In March 2016, the 61-year-old model and reality TV star ... that occurs in the milk ducts, according to an interview with the Daily ...
Breaking Medicine News(10 mins):